JPMorgan Chase & Co. Reiterates Underweight Rating for GSK (LON:GSK)

JPMorgan Chase & Co. reiterated their underweight rating on shares of GSK (LON:GSK - Free Report) in a research note issued to investors on Tuesday, MarketBeat.com reports.

Separately, Berenberg Bank cut their price target on shares of GSK from GBX 1,820 ($22.77) to GBX 1,600 ($20.02) and set a "buy" rating for the company in a research note on Friday, November 29th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of GBX 1,805.83 ($22.59).

GSK Stock Performance

GSK stock traded up GBX 8 ($0.10) during trading hours on Tuesday, reaching GBX 1,357.50 ($16.98). The stock had a trading volume of 5,990,159 shares, compared to its average volume of 7,387,993. The stock has a market capitalization of £55.39 billion, a PE ratio of 1,201.33, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The company has a debt-to-equity ratio of 123.04, a current ratio of 0.82 and a quick ratio of 0.73. The stock has a 50-day simple moving average of GBX 1,358.38 and a 200 day simple moving average of GBX 1,484.76. GSK has a fifty-two week low of GBX 1,282.50 ($16.05) and a fifty-two week high of GBX 1,823.50 ($22.81).

GSK Announces Dividend

The business also recently announced a dividend, which will be paid on Thursday, January 9th. Stockholders of record on Thursday, November 14th will be paid a dividend of GBX 15 ($0.19) per share. This represents a dividend yield of 1.03%. The ex-dividend date of this dividend is Thursday, November 14th. GSK's dividend payout ratio is presently 5,309.73%.

Insider Transactions at GSK

In other GSK news, insider Jonathan Symonds purchased 1,500 shares of the stock in a transaction that occurred on Friday, December 20th. The shares were acquired at an average cost of GBX 1,315 ($16.45) per share, with a total value of £19,725 ($24,677.84). In the last 90 days, insiders purchased 8,658 shares of company stock worth $11,950,792. 1.61% of the stock is owned by insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.